Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 226 entries
Sorted by: Best Match Show Resources per page
Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production.

Blood cancer journal

Khanim FL, Merrick BA, Giles HV, Jankute M, Jackson JB, Giles LJ, Birtwistle J, Bunce CM, Drayson MT.
PMID: 22829072
Blood Cancer J. 2011 Oct;1(10):e39. doi: 10.1038/bcj.2011.38. Epub 2011 Oct 21.

Despite recent therapeutic advancements, multiple myeloma (MM) remains incurable and new therapies are needed, especially for the treatment of elderly and relapsed/refractory patients. We have screened a panel of 100 off-patent licensed oral drugs for anti-myeloma activity and identified...

Cite
Khanim FL, Merrick BA, Giles HV, et al. Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production. Blood Cancer J. 2011;1(10):e39doi: 10.1038/bcj.2011.38.
Khanim, F. L., Merrick, B. A., Giles, H. V., Jankute, M., Jackson, J. B., Giles, L. J., Birtwistle, J., Bunce, C. M., & Drayson, M. T. (2011). Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production. Blood cancer journal, 1(10), e39. https://doi.org/10.1038/bcj.2011.38
Khanim, F L, et al. "Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production." Blood cancer journal vol. 1,10 (2011): e39. doi: https://doi.org/10.1038/bcj.2011.38
Khanim FL, Merrick BA, Giles HV, Jankute M, Jackson JB, Giles LJ, Birtwistle J, Bunce CM, Drayson MT. Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production. Blood Cancer J. 2011 Oct;1(10):e39. doi: 10.1038/bcj.2011.38. Epub 2011 Oct 21. PMID: 22829072; PMCID: PMC3255256.
Copy Download .nbib Format: NLM
A Scoping Review of the Factors That Influence Families' Ability or Capacity to Provide Young People With Emotional Support Over the Transition to Adulthood.

Frontiers in psychology

Stapley E, Vainieri I, Li E, Merrick H, Jeffery M, Foreman S, Casey P, Ullman R, Cortina M.
PMID: 34721198
Front Psychol. 2021 Oct 14;12:732899. doi: 10.3389/fpsyg.2021.732899. eCollection 2021.

The transition to adulthood is typically marked by changes in relationships with family members, peers, and romantic partners. Despite this, the family often maintains a prominent role in young adults' lives. A scoping review was conducted to identify the...

Cite
Stapley E, Vainieri I, Li E, et al. A Scoping Review of the Factors That Influence Families' Ability or Capacity to Provide Young People With Emotional Support Over the Transition to Adulthood. Front Psychol. 2021;12:732899doi: 10.3389/fpsyg.2021.732899.
Stapley, E., Vainieri, I., Li, E., Merrick, H., Jeffery, M., Foreman, S., Casey, P., Ullman, R., & Cortina, M. (2021). A Scoping Review of the Factors That Influence Families' Ability or Capacity to Provide Young People With Emotional Support Over the Transition to Adulthood. Frontiers in psychology, 12732899. https://doi.org/10.3389/fpsyg.2021.732899
Stapley, Emily, et al. "A Scoping Review of the Factors That Influence Families' Ability or Capacity to Provide Young People With Emotional Support Over the Transition to Adulthood." Frontiers in psychology vol. 12 (2021): 732899. doi: https://doi.org/10.3389/fpsyg.2021.732899
Stapley E, Vainieri I, Li E, Merrick H, Jeffery M, Foreman S, Casey P, Ullman R, Cortina M. A Scoping Review of the Factors That Influence Families' Ability or Capacity to Provide Young People With Emotional Support Over the Transition to Adulthood. Front Psychol. 2021 Oct 14;12:732899. doi: 10.3389/fpsyg.2021.732899. eCollection 2021. PMID: 34721198; PMCID: PMC8555465.
Copy Download .nbib Format: NLM
Optimal heating rate in constant pressure and constant flow gas chromatography.

Journal of separation science

Merrick M, Blumberg LM.
PMID: 34245488
J Sep Sci. 2021 Sep;44(17):3254-3267. doi: 10.1002/jssc.202100506. Epub 2021 Aug 06.

Optimal heating rate is the one resulting in the shortest analysis time for achieving a required separation performance of a column. The previously recommended default heating rate (R

Cite
Merrick M, Blumberg LM. Optimal heating rate in constant pressure and constant flow gas chromatography. J Sep Sci. 2021;44(17):3254-3267doi: 10.1002/jssc.202100506.
Merrick, M., & Blumberg, L. M. (2021). Optimal heating rate in constant pressure and constant flow gas chromatography. Journal of separation science, 44(17), 3254-3267. https://doi.org/10.1002/jssc.202100506
Merrick, Mark, and Blumberg, Leonid M. "Optimal heating rate in constant pressure and constant flow gas chromatography." Journal of separation science vol. 44,17 (2021): 3254-3267. doi: https://doi.org/10.1002/jssc.202100506
Merrick M, Blumberg LM. Optimal heating rate in constant pressure and constant flow gas chromatography. J Sep Sci. 2021 Sep;44(17):3254-3267. doi: 10.1002/jssc.202100506. Epub 2021 Aug 06. PMID: 34245488.
Copy Download .nbib Format: NLM
Frequency and Correlates of Mycoplasma genitalium Antimicrobial Resistance Mutations and Their Association With Treatment Outcomes: Findings From a National Sentinel Surveillance Pilot in England.

Sexually transmitted diseases

Fifer H, Merrick R, Pitt R, Yung M, Allen H, Day M, Sinka K, Woodford N, Mohammed H, Brown CS, Hughes G, Cole M.
PMID: 34108410
Sex Transm Dis. 2021 Dec 01;48(12):951-954. doi: 10.1097/OLQ.0000000000001493.

BACKGROUND: Mycoplasma genitalium infection is a public health concern due to extensive antimicrobial resistance. Using data from a pilot of M. genitalium antimicrobial resistance surveillance, we determined the prevalence and risk factors for resistance among specimens from sexual health...

Cite
Fifer H, Merrick R, Pitt R, et al. Frequency and Correlates of Mycoplasma genitalium Antimicrobial Resistance Mutations and Their Association With Treatment Outcomes: Findings From a National Sentinel Surveillance Pilot in England. Sex Transm Dis. 2021;48(12):951-954doi: 10.1097/OLQ.0000000000001493.
Fifer, H., Merrick, R., Pitt, R., Yung, M., Allen, H., Day, M., Sinka, K., Woodford, N., Mohammed, H., Brown, C. S., Hughes, G., Cole, M. (2021). Frequency and Correlates of Mycoplasma genitalium Antimicrobial Resistance Mutations and Their Association With Treatment Outcomes: Findings From a National Sentinel Surveillance Pilot in England. Sexually transmitted diseases, 48(12), 951-954. https://doi.org/10.1097/OLQ.0000000000001493
Fifer, Helen, et al. "Frequency and Correlates of Mycoplasma genitalium Antimicrobial Resistance Mutations and Their Association With Treatment Outcomes: Findings From a National Sentinel Surveillance Pilot in England." Sexually transmitted diseases vol. 48,12 (2021): 951-954. doi: https://doi.org/10.1097/OLQ.0000000000001493
Fifer H, Merrick R, Pitt R, Yung M, Allen H, Day M, Sinka K, Woodford N, Mohammed H, Brown CS, Hughes G, Cole M. Frequency and Correlates of Mycoplasma genitalium Antimicrobial Resistance Mutations and Their Association With Treatment Outcomes: Findings From a National Sentinel Surveillance Pilot in England. Sex Transm Dis. 2021 Dec 01;48(12):951-954. doi: 10.1097/OLQ.0000000000001493. PMID: 34108410.
Copy Download .nbib Format: NLM
Combined epidemiological and genomic analysis of nosocomial SARS-CoV-2 infection early in the pandemic and the role of unidentified cases in transmission.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Snell LB, Fisher CL, Taj U, Stirrup O, Merrick B, Alcolea-Medina A, Charalampous T, Signell AW, Wilson HD, Betancor G, Kia Ik MT, Cunningham E, Cliff PR, Pickering S, Galao RP, Batra R, Neil SJD, Malim MH, Doores KJ, Douthwaite ST, Nebbia G, Edgeworth JD, Awan AR.
PMID: 34400345
Clin Microbiol Infect. 2021 Aug 13; doi: 10.1016/j.cmi.2021.07.040. Epub 2021 Aug 13.

OBJECTIVES: To analyse nosocomial transmission in the early stages of the coronavirus 2019 (COVID-19) pandemic at a large multisite healthcare institution. Nosocomial incidence is linked with infection control interventions.METHODS: Viral genome sequence and epidemiological data were analysed for 574...

Cite
Snell LB, Fisher CL, Taj U, et al. Combined epidemiological and genomic analysis of nosocomial SARS-CoV-2 infection early in the pandemic and the role of unidentified cases in transmission. Clin Microbiol Infect. 2021;doi: 10.1016/j.cmi.2021.07.040.
Snell, L. B., Fisher, C. L., Taj, U., Stirrup, O., Merrick, B., Alcolea-Medina, A., Charalampous, T., Signell, A. W., Wilson, H. D., Betancor, G., Kia Ik, M. T., Cunningham, E., Cliff, P. R., Pickering, S., Galao, R. P., Batra, R., Neil, S. J. D., Malim, M. H., Doores, K. J., Douthwaite, S. T., Nebbia, G., Edgeworth, J. D., Awan, A. R. (2021). Combined epidemiological and genomic analysis of nosocomial SARS-CoV-2 infection early in the pandemic and the role of unidentified cases in transmission. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, . https://doi.org/10.1016/j.cmi.2021.07.040
Snell, Luke B, et al. "Combined epidemiological and genomic analysis of nosocomial SARS-CoV-2 infection early in the pandemic and the role of unidentified cases in transmission." Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases vol. (2021). doi: https://doi.org/10.1016/j.cmi.2021.07.040
Snell LB, Fisher CL, Taj U, Stirrup O, Merrick B, Alcolea-Medina A, Charalampous T, Signell AW, Wilson HD, Betancor G, Kia Ik MT, Cunningham E, Cliff PR, Pickering S, Galao RP, Batra R, Neil SJD, Malim MH, Doores KJ, Douthwaite ST, Nebbia G, Edgeworth JD, Awan AR. Combined epidemiological and genomic analysis of nosocomial SARS-CoV-2 infection early in the pandemic and the role of unidentified cases in transmission. Clin Microbiol Infect. 2021 Aug 13; doi: 10.1016/j.cmi.2021.07.040. Epub 2021 Aug 13. PMID: 34400345; PMCID: PMC8361005.
Copy Download .nbib Format: NLM
Dpp4+ interstitial progenitor cells contribute to basal and high fat diet-induced adipogenesis.

Molecular metabolism

Stefkovich M, Traynor S, Cheng L, Merrick D, Seale P.
PMID: 34662714
Mol Metab. 2021 Dec;54:101357. doi: 10.1016/j.molmet.2021.101357. Epub 2021 Oct 15.

OBJECTIVE: The capacity to generate new adipocytes from precursor cells is critical for maintaining metabolic health. Adipocyte precursor cells (APCs) constitute a heterogenous collection of cell types; however, the contribution of these various cell types to adipose tissue expansion...

Cite
Stefkovich M, Traynor S, Cheng L, et al. Dpp4+ interstitial progenitor cells contribute to basal and high fat diet-induced adipogenesis. Mol Metab. 2021;54:101357doi: 10.1016/j.molmet.2021.101357.
Stefkovich, M., Traynor, S., Cheng, L., Merrick, D., & Seale, P. (2021). Dpp4+ interstitial progenitor cells contribute to basal and high fat diet-induced adipogenesis. Molecular metabolism, 54101357. https://doi.org/10.1016/j.molmet.2021.101357
Stefkovich, Megan, et al. "Dpp4+ interstitial progenitor cells contribute to basal and high fat diet-induced adipogenesis." Molecular metabolism vol. 54 (2021): 101357. doi: https://doi.org/10.1016/j.molmet.2021.101357
Stefkovich M, Traynor S, Cheng L, Merrick D, Seale P. Dpp4+ interstitial progenitor cells contribute to basal and high fat diet-induced adipogenesis. Mol Metab. 2021 Dec;54:101357. doi: 10.1016/j.molmet.2021.101357. Epub 2021 Oct 15. PMID: 34662714; PMCID: PMC8581370.
Copy Download .nbib Format: NLM
Head Over Wheels: Traumatic Head and Neck Injuries Secondary to Mountain Biking.

The Annals of otology, rhinology, and laryngology

Kshirsagar RS, Xiao C, Chou DW, Krishnan S, Christian AB, Labadie KP, Brodsky MA, Liang J.
PMID: 33840222
Ann Otol Rhinol Laryngol. 2022 Jan;131(1):52-58. doi: 10.1177/00034894211007231. Epub 2021 Apr 12.

OBJECTIVES: The popularity of mountain biking (MTB) in the United States has risen in recent years. We sought to identify the prevalence and distribution of MTB associated head and neck injuries presenting to emergency departments across the U.S. and...

Cite
Kshirsagar RS, Xiao C, Chou DW, et al. Head Over Wheels: Traumatic Head and Neck Injuries Secondary to Mountain Biking. Ann Otol Rhinol Laryngol. 2021;131(1):52-58doi: 10.1177/00034894211007231.
Kshirsagar, R. S., Xiao, C., Chou, D. W., Krishnan, S., Christian, A. B., Labadie, K. P., Brodsky, M. A., & Liang, J. (2022). Head Over Wheels: Traumatic Head and Neck Injuries Secondary to Mountain Biking. The Annals of otology, rhinology, and laryngology, 131(1), 52-58. https://doi.org/10.1177/00034894211007231
Kshirsagar, Rijul S, et al. "Head Over Wheels: Traumatic Head and Neck Injuries Secondary to Mountain Biking." The Annals of otology, rhinology, and laryngology vol. 131,1 (2022): 52-58. doi: https://doi.org/10.1177/00034894211007231
Kshirsagar RS, Xiao C, Chou DW, Krishnan S, Christian AB, Labadie KP, Brodsky MA, Liang J. Head Over Wheels: Traumatic Head and Neck Injuries Secondary to Mountain Biking. Ann Otol Rhinol Laryngol. 2022 Jan;131(1):52-58. doi: 10.1177/00034894211007231. Epub 2021 Apr 12. PMID: 33840222.
Copy Download .nbib Format: NLM
Author Correction: A dynamic COVID-19 immune signature includes associations with poor prognosis.

Nature medicine

Laing AG, Lorenc A, Del Molino Del Barrio I, Das A, Fish M, Monin L, Muñoz-Ruiz M, McKenzie DR, Hayday TS, Francos-Quijorna I, Kamdar S, Joseph M, Davies D, Davis R, Jennings A, Zlatareva I, Vantourout P, Wu Y, Sofra V, Cano F, Greco M, Theodoridis E, Freedman JD, Gee S, Chan JNE, Ryan S, Bugallo-Blanco E, Peterson P, Kisand K, Haljasmägi L, Chadli L, Moingeon P, Martinez L, Merrick B, Bisnauthsing K, Brooks K, Ibrahim MAA, Mason J, Lopez Gomez F, Babalola K, Abdul-Jawad S, Cason J, Mant C, Seow J, Graham C, Doores KJ, Di Rosa F, Edgeworth J, Shankar-Hari M, Hayday AC.
PMID: 33247289
Nat Med. 2020 Dec;26(12):1951. doi: 10.1038/s41591-020-01186-5.

A Correction to this paper has been published: https://doi.org/10.1038/s41591-020-01186-5.

Cite
Laing AG, Lorenc A, Del Molino Del Barrio I, et al. Author Correction: A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat Med. 2020;26(12):1951doi: 10.1038/s41591-020-01186-5.
Laing, A. G., Lorenc, A., Del Molino Del Barrio, I., Das, A., Fish, M., Monin, L., Muñoz-Ruiz, M., McKenzie, D. R., Hayday, T. S., Francos-Quijorna, I., Kamdar, S., Joseph, M., Davies, D., Davis, R., Jennings, A., Zlatareva, I., Vantourout, P., Wu, Y., Sofra, V., Cano, F., Greco, M., Theodoridis, E., Freedman, J. D., Gee, S., Chan, J. N. E., Ryan, S., Bugallo-Blanco, E., Peterson, P., Kisand, K., Haljasmägi, L., Chadli, L., Moingeon, P., Martinez, L., Merrick, B., Bisnauthsing, K., Brooks, K., Ibrahim, M. A. A., Mason, J., Lopez Gomez, F., Babalola, K., Abdul-Jawad, S., Cason, J., Mant, C., Seow, J., Graham, C., Doores, K. J., Di Rosa, F., Edgeworth, J., Shankar-Hari, M., & Hayday, A. C. (2020). Author Correction: A dynamic COVID-19 immune signature includes associations with poor prognosis. Nature medicine, 26(12), 1951. https://doi.org/10.1038/s41591-020-01186-5
Laing, Adam G, et al. "Author Correction: A dynamic COVID-19 immune signature includes associations with poor prognosis." Nature medicine vol. 26,12 (2020): 1951. doi: https://doi.org/10.1038/s41591-020-01186-5
Laing AG, Lorenc A, Del Molino Del Barrio I, Das A, Fish M, Monin L, Muñoz-Ruiz M, McKenzie DR, Hayday TS, Francos-Quijorna I, Kamdar S, Joseph M, Davies D, Davis R, Jennings A, Zlatareva I, Vantourout P, Wu Y, Sofra V, Cano F, Greco M, Theodoridis E, Freedman JD, Gee S, Chan JNE, Ryan S, Bugallo-Blanco E, Peterson P, Kisand K, Haljasmägi L, Chadli L, Moingeon P, Martinez L, Merrick B, Bisnauthsing K, Brooks K, Ibrahim MAA, Mason J, Lopez Gomez F, Babalola K, Abdul-Jawad S, Cason J, Mant C, Seow J, Graham C, Doores KJ, Di Rosa F, Edgeworth J, Shankar-Hari M, Hayday AC. Author Correction: A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat Med. 2020 Dec;26(12):1951. doi: 10.1038/s41591-020-01186-5. PMID: 33247289; PMCID: PMC7694581.
Copy Download .nbib Format: NLM
KRAS-retroviral fusion transcripts and gene amplification in arsenic-transformed, human prostate CAsE-PE cancer cells.

Toxicology and applied pharmacology

Merrick BA, Phadke DP, Bostrom MA, Shah RR, Wright GM, Wang X, Gordon O, Pelch KE, Auerbach SS, Paules RS, DeVito MJ, Waalkes MP, Tokar EJ.
PMID: 32344290
Toxicol Appl Pharmacol. 2020 Apr 25;397:115017. doi: 10.1016/j.taap.2020.115017. Epub 2020 Apr 25.

CAsE-PE cells are an arsenic-transformed, human prostate epithelial line containing oncogenic mutations in KRAS compared to immortalized, normal KRAS parent cells, RWPE-1. We previously reported increased copy number of mutated KRAS in CAsE-PE cells, suggesting gene amplification. Here, KRAS...

Cite
Merrick BA, Phadke DP, Bostrom MA, et al. KRAS-retroviral fusion transcripts and gene amplification in arsenic-transformed, human prostate CAsE-PE cancer cells. Toxicol Appl Pharmacol. 2020;397:115017doi: 10.1016/j.taap.2020.115017.
Merrick, B. A., Phadke, D. P., Bostrom, M. A., Shah, R. R., Wright, G. M., Wang, X., Gordon, O., Pelch, K. E., Auerbach, S. S., Paules, R. S., DeVito, M. J., Waalkes, M. P., & Tokar, E. J. (2020). KRAS-retroviral fusion transcripts and gene amplification in arsenic-transformed, human prostate CAsE-PE cancer cells. Toxicology and applied pharmacology, 397115017. https://doi.org/10.1016/j.taap.2020.115017
Merrick, B Alex, et al. "KRAS-retroviral fusion transcripts and gene amplification in arsenic-transformed, human prostate CAsE-PE cancer cells." Toxicology and applied pharmacology vol. 397 (2020): 115017. doi: https://doi.org/10.1016/j.taap.2020.115017
Merrick BA, Phadke DP, Bostrom MA, Shah RR, Wright GM, Wang X, Gordon O, Pelch KE, Auerbach SS, Paules RS, DeVito MJ, Waalkes MP, Tokar EJ. KRAS-retroviral fusion transcripts and gene amplification in arsenic-transformed, human prostate CAsE-PE cancer cells. Toxicol Appl Pharmacol. 2020 Apr 25;397:115017. doi: 10.1016/j.taap.2020.115017. Epub 2020 Apr 25. PMID: 32344290; PMCID: PMC7606314.
Copy Download .nbib Format: NLM
Dysidenin from the Marine Sponge .

Marine drugs

Ramage KS, Taki AC, Lum KY, Hayes S, Byrne JJ, Wang T, Hofmann A, Ekins MG, White JM, Jabbar A, Davis RA, Gasser RB.
PMID: 34940697
Mar Drugs. 2021 Dec 09;19(12). doi: 10.3390/md19120698.

High-throughput screening of the NatureBank marine extract library (

Cite
Ramage KS, Taki AC, Lum KY, et al. Dysidenin from the Marine Sponge . Mar Drugs. 2021;19(12)doi: 10.3390/md19120698.
Ramage, K. S., Taki, A. C., Lum, K. Y., Hayes, S., Byrne, J. J., Wang, T., Hofmann, A., Ekins, M. G., White, J. M., Jabbar, A., Davis, R. A., & Gasser, R. B. (2021). Dysidenin from the Marine Sponge . Marine drugs, 19(12), . https://doi.org/10.3390/md19120698
Ramage, Kelsey S, et al. "Dysidenin from the Marine Sponge ." Marine drugs vol. 19,12 (2021). doi: https://doi.org/10.3390/md19120698
Ramage KS, Taki AC, Lum KY, Hayes S, Byrne JJ, Wang T, Hofmann A, Ekins MG, White JM, Jabbar A, Davis RA, Gasser RB. Dysidenin from the Marine Sponge . Mar Drugs. 2021 Dec 09;19(12). doi: 10.3390/md19120698. PMID: 34940697.
Copy Download .nbib Format: NLM
Monte Carlo evaluation of hypothetical long axial field-of-view PET scanner using GE discovery MI PET front-end architecture.

Medical physics

Tiwari A, Merrick M, Graves SA, Sunderland J.
PMID: 34954831
Med Phys. 2021 Dec 25; doi: 10.1002/mp.15422. Epub 2021 Dec 25.

PURPOSE: The development of total-body PET scanners is of growing interest in the PET community. Investigation into the imaging properties of a hypothetical extended axial field-of-view (AFOV) GE Healthcare SiPM-based Discovery MI (DMI) system architecture has not yet been...

Cite
Tiwari A, Merrick M, Graves SA, et al. Monte Carlo evaluation of hypothetical long axial field-of-view PET scanner using GE discovery MI PET front-end architecture. Med Phys. 2021;doi: 10.1002/mp.15422.
Tiwari, A., Merrick, M., Graves, S. A., & Sunderland, J. (2021). Monte Carlo evaluation of hypothetical long axial field-of-view PET scanner using GE discovery MI PET front-end architecture. Medical physics, . https://doi.org/10.1002/mp.15422
Tiwari, Ashok, et al. "Monte Carlo evaluation of hypothetical long axial field-of-view PET scanner using GE discovery MI PET front-end architecture." Medical physics vol. (2021). doi: https://doi.org/10.1002/mp.15422
Tiwari A, Merrick M, Graves SA, Sunderland J. Monte Carlo evaluation of hypothetical long axial field-of-view PET scanner using GE discovery MI PET front-end architecture. Med Phys. 2021 Dec 25; doi: 10.1002/mp.15422. Epub 2021 Dec 25. PMID: 34954831.
Copy Download .nbib Format: NLM
Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections.

medRxiv : the preprint server for health sciences

Dupont L, Snell LB, Graham C, Seow J, Merrick B, Lechmere T, Hallett SR, Charalampous T, Alcolea-Medina A, Huettner I, Maguire TJA, Acors S, Almeida N, Cox D, Dickenson RE, Galao RP, Jimenez-Guardeño JM, Kouphou N, Lista MJ, Pickering S, Ortega-Prieto AM, Wilson H, Winstone H, Fairhead C, Su J, Nebbia G, Batra R, Neil S, Shankar-Hari M, Edgeworth JD, Malim MH, Doores KJ.
PMID: 34127977
medRxiv. 2021 Jun 08; doi: 10.1101/2021.06.07.21258351.

As SARS-CoV-2 variants continue to emerge globally, a major challenge for COVID-19 vaccination is the generation of a durable antibody response with cross-neutralizing activity against both current and newly emerging viral variants. Cross-neutralizing activity against major variants of concern...

Cite
Dupont L, Snell LB, Graham C, et al. Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections. medRxiv. 2021;doi: 10.1101/2021.06.07.21258351.
Dupont, L., Snell, L. B., Graham, C., Seow, J., Merrick, B., Lechmere, T., Hallett, S. R., Charalampous, T., Alcolea-Medina, A., Huettner, I., Maguire, T. J. A., Acors, S., Almeida, N., Cox, D., Dickenson, R. E., Galao, R. P., Jimenez-Guardeño, J. M., Kouphou, N., Lista, M. J., Pickering, S., Ortega-Prieto, A. M., Wilson, H., Winstone, H., Fairhead, C., Su, J., Nebbia, G., Batra, R., Neil, S., Shankar-Hari, M., Edgeworth, J. D., Malim, M. H., & Doores, K. J. (2021). Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2021.06.07.21258351
Dupont, Liane, et al. "Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2021.06.07.21258351
Dupont L, Snell LB, Graham C, Seow J, Merrick B, Lechmere T, Hallett SR, Charalampous T, Alcolea-Medina A, Huettner I, Maguire TJA, Acors S, Almeida N, Cox D, Dickenson RE, Galao RP, Jimenez-Guardeño JM, Kouphou N, Lista MJ, Pickering S, Ortega-Prieto AM, Wilson H, Winstone H, Fairhead C, Su J, Nebbia G, Batra R, Neil S, Shankar-Hari M, Edgeworth JD, Malim MH, Doores KJ. Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections. medRxiv. 2021 Jun 08; doi: 10.1101/2021.06.07.21258351. PMID: 34127977; PMCID: PMC8202432.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 226 entries